Nectar Lifesciences AGM: Auditors issue clean opinion for FY26
- Nectar Lifesciences held its 31st AGM on September 18, 2026
- Statutory auditors issued an unqualified opinion for FY26
- Chairman Sanjiv Goyal was reappointed by rotation
- Two independent directors were reappointed for their second terms
- Dr. Gunmala Suri was appointed as a non-executive director

*this image is generated using AI for illustrative purposes only.
Nectar Lifesciences held its 31st annual general meeting on September 18, 2026, where shareholders approved the adoption of standalone and consolidated financial statements for FY26.
The meeting, conducted via video conferencing, saw the reappointment of Chairman Sanjiv Goyal and independent directors Dr. Kuldip Kumar Bhasin and Dr. Indu Pal Kaur. Dr. Gunmala Suri was appointed as a non-executive non-independent director.
Audit and Governance
Statutory auditors M/s. Deepak Jindal & Co., Chartered Accountants, and secretarial auditors P. Chadha & Associates expressed an unqualified opinion on the financial year 2025-26 results. No qualifications or adverse comments were noted in the audit reports regarding the company’s functioning or financial statements.
KFin Technologies Limited served as the registrar and share transfer agent, facilitating remote e-voting from September 15 to September 17, 2026, and instant polling during the AGM. Mr. Prince Chadha acted as the scrutinizer for the voting process.
Board Appointments
The following resolutions were passed during the ordinary and special business segments:
| Director | Role | Action |
|---|---|---|
| Sanjiv Goyal | Chairman & Managing Director | Reappointed by rotation |
| Dr. Kuldip Kumar Bhasin | Independent Director | Reappointed for second term |
| Dr. Indu Pal Kaur | Independent Director | Reappointed for second term |
| Dr. Gunmala Suri | Non-Executive Non-Independent Director | Appointed |
Chairman Sanjiv Goyal thanked members for their trust and acknowledged the commitment of the company’s workforce. The meeting concluded at 11:25 am.
Historical Stock Returns for Nectar Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.45% | -8.05% | -2.32% | +0.18% | -34.11% | -62.75% |
How might the appointment of Dr. Gunmala Suri as a non-executive non-independent director influence Nectar Lifesciences' strategic direction and board dynamics?
Given the clean audit opinion for FY26, what specific growth initiatives or capital allocation strategies is management expected to prioritize in the upcoming fiscal year?
Will the reappointment of key independent directors signal continuity in corporate governance standards, or are there anticipated changes to the company's risk management framework?

































